E-7820
- CAS No.
- 289483-69-8
- Chemical Name:
- E-7820
- Synonyms
- E-7820;CS-2701;ER 68203-00;E 7820; E-7820;E7820, 10 mM in DMSO;ER68203-00;E7820;E-7820;E 7820;289483-69-8;3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide;N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide;Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-;E7820,cell,tumor,WiDr,derivative,Integrin,colorectal,LoVo,inhibit,Inhibitor,sulfonamide,HUVEC,endothelium,E 7820,E-7820
- CBNumber:
- CB61011214
- Molecular Formula:
- C17H12N4O2S
- Molecular Weight:
- 336.37
- MDL Number:
- MFCD09833234
- MOL File:
- 289483-69-8.mol
- MSDS File:
- SDS
| Boiling point | 626.2±65.0 °C(Predicted) |
|---|---|
| Density | 1.48±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:67.0(Max Conc. mg/mL);199.19(Max Conc. mM) |
| form | A crystalline solid |
| pka | 8.17±0.30(Predicted) |
| color | Light yellow to light brown |
| FDA UNII | TVH5K7949N |
| NCI Drug Dictionary | E7820 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
E-7820 price More Price(19)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 25502 | E7820 ≥98% | 289483-69-8 | 5mg | $37 | 2024-03-01 | Buy |
| Cayman Chemical | 25502 | E7820 ≥98% | 289483-69-8 | 10mg | $68 | 2024-03-01 | Buy |
| Cayman Chemical | 25502 | E7820 ≥98% | 289483-69-8 | 50mg | $283 | 2024-03-01 | Buy |
| Cayman Chemical | 25502 | E7820 ≥98% | 289483-69-8 | 100mg | $530 | 2024-03-01 | Buy |
| Tocris | 6785 | E7820 ≥98%(HPLC) | 289483-69-8 | 10 | $207 | 2021-12-16 | Buy |
E-7820 Chemical Properties,Uses,Production
Description
E7820 is a sulfonamide derivative and an angiogenesis inhibitor that inhibits bFGF- and VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation (IC50s = 0.1 and 0.081 μg/ml, respectively). It inhibits bFGF- and VEGF-stimulated tube formation of HUVECs in a concentration-dependent manner (IC50s = 0.2 and 0.24 μg/ml, respectively). E7820 selectively decreases the surface expression and mRNA levels of integrin α2 over CD31 and VE-cadherin in HUVECs. In vivo, E7820 (200 and 400 mg/kg) reduces tumor growth and inhibits angiogenesis in a WiDr colorectal cancer mouse xenograft model. It also reduces tumor weight in a panel of seven human colon, breast, pancreas, and kidney cancer mouse xenograft models, completely inhibits tumor growth in KP-1 pancreatic and LoVo colon cancer mouse xenograft models, and inhibits tumor growth in KP-1 and COLO 320DM mouse orthotopic transplantation models.
Uses
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity[1][2].
reaction suitability
reagent type: ligand
in vivo
E7820 (ER68203-00) (50-200 mg/kg; p.o. ; twice daily for 14 days) delays the growth of WiDr cells inoculated s.c.[1].
E7820 (200-400 mg/kg; p.o.;once daily for 4 days) potently inhibits WiDr-induced angiogenesis[1].
| Animal Model: | Six-week-old female nude mice (KSN mice, WiDr-induced angiogenesis model) [1] |
| Dosage: | 50, 100, 200 mg/kg |
| Administration: | p.o. ; twice daily for 14 days from 2 days after inoculation of the tumor cells |
| Result: | The antitumor effect was dose-dependent at 50, 100, and 200 mg/kg, and the tumor growth rates were 52%, 46%, and 27%, respectively. |
storage
Store at -20°C
References
[1] Funahashi Y, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116-6123. PMID:12414636
[2] Ito K, et al. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023-1031. DOI:10.1111/cas.12450
E-7820 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32159 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30231 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38630 | 58 | |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131957 | 58 |
| Shanghai Dongyang Biotechnology Co., Ltd. | 0512-0512-13601744364 13601744364 | chemsharker@126.com | China | 947 | 58 |
| Shanghai Boyle Chemical Co., Ltd. | sales@boylechem.com | China | 2922 | 55 |
